TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT
The emergence of drug resistance is a major obstacle in the treatment of cancer patients. Here, the authors show that TRIB2 expression increases resistance to PI3K inhibition by promoting AKT activation and the subsequent FOXO inactivation and disruption of p53 function.
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | article |
| Language: | EN |
| Published: |
Nature Portfolio
2017
|
| Subjects: | |
| Online Access: | https://doaj.org/article/176359cfd25c4c82970d73e492cb40ae |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Be the first to leave a comment!